Vertex Pharmaceuticals Incorporated (0QZU.L)
USD 499.1
(-0.75%)
USD 499.1
(-0.75%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 8.6 Billion USD | 9.25% |
| 2022 | 7.85 Billion USD | 17.69% |
| 2021 | 6.67 Billion USD | 21.96% |
| 2020 | 5.46 Billion USD | 51.29% |
| 2019 | 3.61 Billion USD | 37.04% |
| 2018 | 2.63 Billion USD | 19.18% |
| 2017 | 2.21 Billion USD | 48.39% |
| 2016 | 1.49 Billion USD | 64.5% |
| 2015 | 906.79 Million USD | 74.58% |
| 2014 | 519.42 Million USD | -51.98% |
| 2013 | 1.08 Billion USD | -13.27% |
| 2012 | 1.24 Billion USD | -6.24% |
| 2011 | 1.33 Billion USD | 918.16% |
| 2010 | 130.64 Million USD | 48.71% |
| 2009 | 87.84 Million USD | -45.03% |
| 2008 | 159.81 Million USD | -13.66% |
| 2007 | 185.1 Million USD | -9.34% |
| 2006 | 204.18 Million USD | 35.41% |
| 2005 | 150.79 Million USD | 55.35% |
| 2004 | 97.06 Million USD | 47.04% |
| 2003 | 66.01 Million USD | -50.29% |
| 2002 | 132.8 Million USD | 3.87% |
| 2001 | 127.86 Million USD | 72.68% |
| 2000 | 74.04 Million USD | 13.92% |
| 1999 | 65 Million USD | 32.92% |
| 1998 | 48.9 Million USD | 3.16% |
| 1997 | 47.4 Million USD | 187.27% |
| 1996 | 16.5 Million USD | -36.05% |
| 1995 | 25.8 Million USD | 11.69% |
| 1994 | 23.1 Million USD | -27.36% |
| 1993 | 31.8 Million USD | 381.82% |
| 1992 | 6.6 Million USD | 32.0% |
| 1991 | 5 Million USD | 117.39% |
| 1990 | 2.3 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 2.37 Billion USD | 5.15% |
| 2024 Q2 | 2.26 Billion USD | -3.49% |
| 2024 Q1 | 2.34 Billion USD | 9.07% |
| 2023 Q1 | 2.1 Billion USD | 4.38% |
| 2023 Q4 | 2.14 Billion USD | -0.7% |
| 2023 FY | 8.57 Billion USD | 9.25% |
| 2023 Q2 | 2.18 Billion USD | 3.64% |
| 2023 Q3 | 2.16 Billion USD | -0.91% |
| 2022 Q4 | 2.01 Billion USD | -1.25% |
| 2022 Q1 | 1.85 Billion USD | 1.45% |
| 2022 Q2 | 1.93 Billion USD | 4.47% |
| 2022 FY | 7.85 Billion USD | 17.69% |
| 2022 Q3 | 2.04 Billion USD | 5.71% |
| 2021 Q1 | 1.53 Billion USD | 7.53% |
| 2021 Q2 | 1.56 Billion USD | 2.18% |
| 2021 Q4 | 1.82 Billion USD | 4.44% |
| 2021 FY | 6.67 Billion USD | 21.96% |
| 2021 Q3 | 1.74 Billion USD | 11.64% |
| 2020 Q1 | 1.35 Billion USD | 10.12% |
| 2020 FY | 5.46 Billion USD | 51.29% |
| 2020 Q4 | 1.42 Billion USD | 5.37% |
| 2020 Q3 | 1.35 Billion USD | 0.9% |
| 2020 Q2 | 1.33 Billion USD | -0.93% |
| 2019 FY | 3.61 Billion USD | 37.04% |
| 2019 Q1 | 763.34 Million USD | 2.08% |
| 2019 Q4 | 1.22 Billion USD | 50.17% |
| 2019 Q3 | 817.91 Million USD | 1.53% |
| 2019 Q2 | 805.55 Million USD | 5.53% |
| 2018 Q2 | 647.77 Million USD | 13.81% |
| 2018 Q4 | 747.81 Million USD | 11.07% |
| 2018 FY | 2.63 Billion USD | 19.18% |
| 2018 Q1 | 569.18 Million USD | 0.28% |
| 2018 Q3 | 673.28 Million USD | 3.94% |
| 2017 Q3 | 505.29 Million USD | 6.84% |
| 2017 Q2 | 472.93 Million USD | -29.17% |
| 2017 Q1 | 667.73 Million USD | 67.68% |
| 2017 Q4 | 567.58 Million USD | 12.33% |
| 2017 FY | 2.21 Billion USD | 48.39% |
| 2016 Q2 | 386.35 Million USD | 11.2% |
| 2016 FY | 1.49 Billion USD | 64.5% |
| 2016 Q1 | 347.43 Million USD | -1.72% |
| 2016 Q3 | 359.7 Million USD | -6.9% |
| 2016 Q4 | 398.22 Million USD | 10.71% |
| 2015 Q4 | 353.52 Million USD | 27.23% |
| 2015 Q1 | 126.2 Million USD | -3.31% |
| 2015 Q2 | 149.21 Million USD | 18.24% |
| 2015 FY | 906.79 Million USD | 74.58% |
| 2015 Q3 | 277.85 Million USD | 86.21% |
| 2014 Q3 | 164.8 Million USD | 36.06% |
| 2014 Q2 | 121.12 Million USD | 17.62% |
| 2014 Q4 | 130.52 Million USD | -20.8% |
| 2014 FY | 519.42 Million USD | -51.98% |
| 2014 Q1 | 102.97 Million USD | -68.69% |
| 2013 Q3 | 194.36 Million USD | -28.76% |
| 2013 Q2 | 272.81 Million USD | -4.48% |
| 2013 Q1 | 285.62 Million USD | 15.98% |
| 2013 Q4 | 328.89 Million USD | 69.22% |
| 2013 FY | 1.08 Billion USD | -13.27% |
| 2012 Q4 | 246.27 Million USD | -17.21% |
| 2012 Q3 | 297.47 Million USD | -2.11% |
| 2012 Q2 | 303.88 Million USD | -23.94% |
| 2012 Q1 | 399.52 Million USD | -25.07% |
| 2012 FY | 1.24 Billion USD | -6.24% |
| 2011 FY | 1.33 Billion USD | 918.16% |
| 2011 Q1 | 70.99 Million USD | 13.64% |
| 2011 Q2 | 105.11 Million USD | 48.06% |
| 2011 Q3 | 620.79 Million USD | 490.57% |
| 2011 Q4 | 533.21 Million USD | -14.11% |
| 2010 Q4 | 62.47 Million USD | 203.76% |
| 2010 FY | 130.64 Million USD | 48.71% |
| 2010 Q1 | 19.06 Million USD | -36.97% |
| 2010 Q2 | 28.53 Million USD | 49.7% |
| 2010 Q3 | 20.56 Million USD | -27.93% |
| 2009 Q1 | 20.4 Million USD | -28.65% |
| 2009 Q4 | 30.24 Million USD | 42.35% |
| 2009 FY | 87.84 Million USD | -45.03% |
| 2009 Q2 | 15.79 Million USD | -22.58% |
| 2009 Q3 | 21.24 Million USD | 34.49% |
| 2008 FY | 159.81 Million USD | -13.66% |
| 2008 Q1 | 38.09 Million USD | -19.49% |
| 2008 Q3 | 27.41 Million USD | -58.28% |
| 2008 Q2 | 65.7 Million USD | 72.47% |
| 2008 Q4 | 28.59 Million USD | 4.31% |
| 2007 Q2 | 34.79 Million USD | -46.91% |
| 2007 Q1 | 65.54 Million USD | -28.04% |
| 2007 FY | 185.1 Million USD | -9.34% |
| 2007 Q3 | 37.45 Million USD | 7.64% |
| 2007 Q4 | 47.32 Million USD | 26.35% |
| 2006 FY | 204.18 Million USD | 35.41% |
| 2006 Q4 | 91.07 Million USD | 81.52% |
| 2006 Q3 | 50.17 Million USD | 86.94% |
| 2006 Q2 | 26.84 Million USD | -25.63% |
| 2006 Q1 | 36.09 Million USD | -40.81% |
| 2005 Q4 | 60.97 Million USD | 82.49% |
| 2005 Q2 | 29.83 Million USD | 12.25% |
| 2005 Q3 | 33.41 Million USD | 12.0% |
| 2005 FY | 150.79 Million USD | 55.35% |
| 2005 Q1 | 26.57 Million USD | -29.74% |
| 2004 Q3 | 25.36 Million USD | 47.34% |
| 2004 Q2 | 17.21 Million USD | 3.28% |
| 2004 Q1 | 16.66 Million USD | 12.36% |
| 2004 FY | 97.06 Million USD | 47.04% |
| 2004 Q4 | 37.82 Million USD | 49.14% |
| 2003 Q2 | 16.03 Million USD | -16.01% |
| 2003 Q4 | 14.83 Million USD | -11.18% |
| 2003 Q3 | 16.7 Million USD | 4.13% |
| 2003 Q1 | 19.09 Million USD | -48.65% |
| 2003 FY | 66.01 Million USD | -50.29% |
| 2002 Q1 | 32.05 Million USD | -23.42% |
| 2002 FY | 132.8 Million USD | 3.87% |
| 2002 Q3 | 27.69 Million USD | -22.78% |
| 2002 Q4 | 37.18 Million USD | 34.24% |
| 2002 Q2 | 35.86 Million USD | 11.9% |
| 2001 Q2 | 20.52 Million USD | 12.63% |
| 2001 Q3 | 29.7 Million USD | 44.75% |
| 2001 Q1 | 18.22 Million USD | 47.63% |
| 2001 Q4 | 41.85 Million USD | 40.9% |
| 2001 FY | 127.86 Million USD | 72.68% |
| 2000 Q2 | 38.04 Million USD | 341.04% |
| 2000 FY | 74.04 Million USD | 13.92% |
| 2000 Q4 | 12.34 Million USD | -17.9% |
| 2000 Q3 | 15.03 Million USD | -60.49% |
| 2000 Q1 | 8.62 Million USD | -71.81% |
| 1999 Q2 | 15.5 Million USD | 198.08% |
| 1999 Q1 | 5.2 Million USD | -60.31% |
| 1999 FY | 65 Million USD | 32.92% |
| 1999 Q3 | 10.6 Million USD | -31.61% |
| 1999 Q4 | 30.6 Million USD | 188.68% |
| 1998 Q4 | 13.1 Million USD | -32.82% |
| 1998 FY | 48.9 Million USD | 3.16% |
| 1998 Q1 | 4.1 Million USD | -66.39% |
| 1998 Q2 | 8.3 Million USD | 102.44% |
| 1998 Q3 | 19.5 Million USD | 134.94% |
| 1997 Q1 | 7.7 Million USD | 40.0% |
| 1997 Q2 | 13 Million USD | 68.83% |
| 1997 Q4 | 12.2 Million USD | -15.86% |
| 1997 Q3 | 14.5 Million USD | 11.54% |
| 1997 FY | 47.4 Million USD | 187.27% |
| 1996 Q2 | 4 Million USD | 21.21% |
| 1996 Q4 | 5.5 Million USD | 48.65% |
| 1996 FY | 16.5 Million USD | -36.05% |
| 1996 Q3 | 3.7 Million USD | -7.5% |
| 1996 Q1 | 3.3 Million USD | -64.13% |
| 1995 Q1 | 6.1 Million USD | 64.86% |
| 1995 FY | 25.8 Million USD | 11.69% |
| 1995 Q3 | 3.3 Million USD | -54.17% |
| 1995 Q4 | 9.2 Million USD | 178.79% |
| 1995 Q2 | 7.2 Million USD | 18.03% |
| 1994 FY | 23.1 Million USD | -27.36% |
| 1994 Q1 | 6.5 Million USD | -65.97% |
| 1994 Q2 | 5.7 Million USD | -12.31% |
| 1994 Q4 | 3.7 Million USD | -49.32% |
| 1994 Q3 | 7.3 Million USD | 28.07% |
| 1993 FY | 31.8 Million USD | 381.82% |
| 1993 Q1 | 1.7 Million USD | 0.0% |
| 1993 Q2 | 5.5 Million USD | 223.53% |
| 1993 Q4 | 19.1 Million USD | 260.38% |
| 1993 Q3 | 5.3 Million USD | -3.64% |
| 1992 Q2 | -1 Million USD | -166.67% |
| 1992 Q1 | 1.5 Million USD | 15.38% |
| 1992 FY | 6.6 Million USD | 32.0% |
| 1992 Q3 | 1.7 Million USD | 270.0% |
| 1992 Q4 | 1.7 Million USD | 0.0% |
| 1991 Q1 | 800 Thousand USD | 33.33% |
| 1991 Q4 | 1.3 Million USD | 8.33% |
| 1991 FY | 5 Million USD | 117.39% |
| 1991 Q3 | 1.2 Million USD | -7.69% |
| 1991 Q2 | 1.3 Million USD | 62.5% |
| 1990 Q1 | 500 Thousand USD | 0.0% |
| 1990 Q2 | 600 Thousand USD | 20.0% |
| 1990 Q4 | 600 Thousand USD | 0.0% |
| 1990 Q3 | 600 Thousand USD | 0.0% |
| 1990 FY | 2.3 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | -388477.878% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -2849900.0% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 10200.216% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -49596.865% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 2749940.256% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -58078.991% |
| Imunon, Inc. | -720 Thousand USD | 1195508.365% |
| Dynavax Technologies Corporation | 182.11 Million USD | -4626.083% |
| Editas Medicine, Inc. | -99.52 Million USD | 8747.818% |
| FibroGen, Inc. | 128.9 Million USD | -6577.062% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 90074.911% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 2840694.059% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | -365.898% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -687.471% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -1543.366% |
| Verastem, Inc. | -62 Thousand USD | 13882358.065% |
| Zoetis Inc. | 5.83 Billion USD | -47.532% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 19089.52% |
| Homology Medicines, Inc. | -7.22 Million USD | 119162.111% |
| Nektar Therapeutics | 53.47 Million USD | -15994.469% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 2947702.74% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 43792.573% |
| Perrigo Company plc | 1.68 Billion USD | -412.199% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -11679.6% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 67.55% |
| Illumina, Inc. | 2.74 Billion USD | -213.666% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 43.464% |
| IQVIA Holdings Inc. | 5.23 Billion USD | -64.287% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -85610.018% |
| Waters Corporation | 1.76 Billion USD | -388.703% |
| Biogen Inc. | 7.3 Billion USD | -17.869% |
| Evolus, Inc. | 140.52 Million USD | -6024.845% |
| Adicet Bio, Inc. | -6.09 Million USD | 141244.638% |
| bluebird bio, Inc. | -4.03 Million USD | 213673.201% |
| Geron Corporation | -123.5 Million USD | 7069.061% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -467.039% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -2277.427% |
| Myriad Genetics, Inc. | 476.4 Million USD | -1706.675% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 2258.257% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -296.805% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 27715.163% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | -351.96% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 23.841% |
| Agilent Technologies, Inc. | 3.46 Billion USD | -148.398% |
| OPKO Health, Inc. | 318.12 Million USD | -2605.523% |
| Exelixis, Inc. | 1.75 Billion USD | -389.685% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -1708.596% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -3419.742% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -1005.568% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -1251.407% |
| Blueprint Medicines Corporation | 236.58 Million USD | -3538.031% |
| Insmed Incorporated | 239.63 Million USD | -3491.712% |
| TG Therapeutics, Inc. | 219.1 Million USD | -3828.2% |
| Incyte Corporation | 3.44 Billion USD | -150.156% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -2402.762% |